NAD+ IV Therapy: Evidence, Benefits & What It Costs

NAD+ IV therapy is the most heavily marketed — and most expensive — way to "boost your NAD+." Clinics and mobile-drip services promise an immediate lift in energy, mental clarity, recovery, and even anti-aging, delivered straight into your bloodstream over a few hours. The price tag matches the promise: a single infusion commonly runs several hundred dollars. So it's worth asking the uncomfortable question plainly, before you book one: what does the human evidence actually show for intravenous NAD+ — and is it worth the cost?

The honest answer is that the gap between the marketing and the science here is unusually wide. This page lays out what is genuinely known, what is merely assumed, and what an IV drip realistically costs.

Featured partner

CoreAge Rx

From $93/mo

Check availabilityRead our review

Affiliate link. We may earn a commission at no extra cost to you.

Affiliate partner

Embody

NAD+ injection or nasal spray, dosing protocol published

See Embody↗

A newer comparison concerns NR infusions versus NAD+ infusions; its small retrospective design can inform tolerability questions, but cannot establish a health advantage.

Adding another ingredient does not fill the outcome gap. Our NAD+ and glutathione comparison separates oral biomarker findings from claims about an IV combination.

What NAD+ IV therapy is

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell. It carries electrons through the reactions that turn food into usable cellular energy, and it also fuels DNA-repair enzymes and the sirtuin proteins. Because it sits at the center of energy metabolism, low NAD+ availability can ripple outward into mitochondrial and metabolic dysfunction ¹. NAD+ also tends to fall with age: a study of human tissue documented age-associated declines in NAD+ alongside rising oxidative stress ². That age-related decline is the entire rationale behind "NAD+ restoration."

IV therapy takes that idea to its most literal extreme. Rather than swallowing a precursor and letting your body convert it, an NAD+ drip delivers NAD+ itself directly into a vein, typically infused slowly over two to six hours because faster rates cause uncomfortable side effects (more on that below). The pitch is intuitive: skip the gut, flood the bloodstream, and you've topped up your tank.

The intuition is where the trouble starts.

Human IV NAD+ studies: metabolism and short-term tolerability

A 2019 pilot studied eight participants receiving NAD+ and three saline controls, tracking plasma and urine metabolites during a six-hour infusion ³. It investigated the biochemical fate of infused NAD+, rather than testing claims about energy, cognition or longevity.

What it showed: Plasma NAD+ did not significantly rise during the first two hours of infusion. For much of the infusion, the body appeared to be metabolizing the NAD+ before free NAD+ rose measurably in plasma, with the metabolite signature shifting over the six hours ³. In other words, even a long, slow IV doesn't simply "fill up" your blood with NAD+ on contact the way the marketing implies.

What it did not show: any clinical benefit. This was a small pilot focused on the metabolome — the biochemical fate of the infused NAD+ — not a trial of energy, cognition, recovery, or aging. Its saline controls did not provide a test of how people felt or performed. It therefore informs pharmacokinetics, not routine wellness benefits.

A 2026 retrospective commercial-clinic pilot compared four consecutive daily 500mg NAD+ or NR infusions with 30-day follow-up ¹². It assessed tolerability, vital signs, safety markers and exploratory metabolic measures. NAD+ recipients reported gastrointestinal symptoms, increased heart rate and chest pressure; symptoms resolved by infusion completion. This was not a randomized efficacy trial. All authors disclosed employment by Restore Hyperwellness, an important commercial conflict. It adds short-term human data, without establishing better energy, cognition, recovery or longevity.

What remains unproven for routine wellness

Here is the part the clinic industry tends to skip, stated plainly: there is no rigorous randomized controlled trial showing that intravenous NAD+ improves energy, focus, recovery, or any aging-related outcome in humans. The larger randomized literature on NAD-related biomarkers concerns oral precursors — NMN and nicotinamide riboside (NR). The IV pilots answer narrower metabolism and tolerability questions.

And it matters that those oral trials are the evidence base, because they are sobering even on their own terms. Oral NMN reliably raises blood NAD+ in a dose-dependent way and is well tolerated ⁵; a pharmaceutical-grade NMN formulation cleanly increased circulating NAD+ and its metabolome ⁶; and chronic NR elevates NAD+ in healthy older adults ⁷. Oral NR's pharmacokinetics in humans are well characterized — it raises blood NAD+ predictably ⁴. So precursors clearly hit the biochemical target.

But raising the biomarker is not the same as improving health, and that distinction is where NAD+ marketing collapses. When NR augmented the aged human muscle NAD+ metabolome, it did not improve muscle bioenergetics or physical performance — the fuel gauge moved, the engine output didn't ⁸. When NR raised blood NAD+ roughly 2.6-fold in older adults with mild cognitive impairment, neurocognitive scores were unchanged ⁹. A systematic review and meta-analysis of NAD+ precursors on metabolic-syndrome parameters found clinical benefits to be limited and inconsistent despite reliably raised NAD+ ¹⁰. If the oral precursors — the ones with real trials — struggle to convert higher NAD+ into felt benefits, the IV route cannot claim better routine wellness results from these preliminary pilots. We walk through this evidence in depth in our pillar guide to NAD+ therapy evidence.

The benefits clinics promise vs. what's proven

It's worth lining the two up directly:

• •"Instant energy." The mechanism (NAD+ fuels ATP production) is real, but human trials of NAD+ precursors do not reliably translate raised NAD+ into more felt energy — and controlled IV trials have not established this benefit. See does NAD+ actually boost energy for the trial-by-trial breakdown.
• •"Mental clarity / focus." The one dedicated cognition trial (oral NR in mild cognitive impairment) raised NAD+ but left cognition unchanged ⁹. There is no IV cognition trial.
• •"Anti-aging / cellular rejuvenation." This rests on the NAD+–sirtuin mechanism and animal data, not human outcomes; no NAD+ precursor has been shown to extend human lifespan or reverse aging, and IV pilots have not established an anti-aging benefit. See is NAD+ really anti-aging.
• •"Addiction recovery / 'NAD+ for withdrawal.'" This is a common clinic pitch, but it rests on case series and anecdote, not controlled trials — see NAD+ IV therapy for addiction recovery for why it should never replace evidence-based treatment.
• •"Long COVID / chronic fatigue recovery." The mechanism (COVID disturbs the tryptophan/NAD+ pathway) is plausible, but the direct human evidence is one small uncontrolled pilot — see NAD+ for long COVID and ME/CFS for what the early trials really show.
• •"Mood / depression / anxiety reset." The mitochondria-and-depression link is real research, but the one placebo-controlled NAD+ booster trial found no mood benefit — see NAD+ IV therapy for depression and anxiety.
• •"Hangover cure / morning-after recovery." Metabolizing alcohol genuinely consumes NAD+, but no controlled human trial shows an NAD+ drip cures a hangover — see does NAD+ cure a hangover for why the theory outruns the data.

The pattern is consistent: oral precursor trials and IV pilots measure different interventions and endpoints. Neither metabolism data nor short-term tolerability establishes the routine wellness benefits marketed for IV NAD+.

Side effects and safety

The most reliable, well-documented effect of NAD+ IV therapy is, ironically, its side effects during infusion. The 2026 pilot documented gastrointestinal symptoms, increased heart rate and chest pressure during NAD+ infusion; participants adjusted infusion speed to tolerance ¹². The 2019 pilot did not report adverse events under its slow infusion protocol ³. Small, short studies cannot establish the frequency of reactions across clinical practice or the safety of every formulation. For how these reactions compare across drips, injections, and oral precursors, see our route-by-route breakdown of NAD+ side effects.

On longer-term safety, what reassurance exists again comes from the oral literature: a dedicated safety trial of high-dose NR (3,000 mg/day) found it generally safe and well tolerated ¹¹, and tolerability has been consistent across the oral NMN and NR trials. But "safe in oral trials" does not automatically transfer to repeated high-dose intravenous administration, which has not been studied for long-term safety. As with any IV procedure, there are also the ordinary risks of intravenous access — infection, vein irritation, and the need for proper clinical oversight.

What NAD+ IV therapy actually costs

This is where the value question gets sharp. NAD+ IV therapy is expensive, and pricing is set entirely by clinics and mobile-drip services — there's no insurance coverage, because it's not an approved treatment for any condition. (For the full 2026 breakdown of session prices, package costs, and the maintenance-upsell math, see how much NAD+ IV therapy costs.)

Typical real-world pricing in the US looks roughly like this:

• •A single IV NAD+ infusion commonly runs about $300–$1,000+, depending on the dose (often quoted as 250 mg up to 1,000 mg or more) and whether it's in-clinic or a premium mobile/at-home visit. Getting a figure in advance is not a given: the largest mobile-IV operator we cover, Drip Hydration, now publishes $499 for 250 mg, $799 for 500 mg and $999 for 1,000 mg per IV session.
• •Multi-session "loading" protocols — clinics frequently recommend a series of 4 to 10 infusions, then "maintenance" drips every week or two — push the total into the low thousands of dollars. (That maintenance interval is also where the "lasts 7–14 days" claim comes from — a scheduling convention, not pharmacology, as we explain in how long does NAD+ IV therapy last?.)
• •Add-ons (vitamin/glutathione "cocktails," concierge fees) raise the bill further.

Put bluntly: you can spend several thousand dollars on a course of infusions for which there is no controlled human evidence of benefit. By contrast, oral NMN or NR — the routes that actually have human trials showing they raise NAD+ — cost a small fraction of that per month. That doesn't make the oral precursors a proven path to energy or longevity (they aren't), but it does mean you'd be paying a steep premium for the IV route's unproven delivery method, not for better-proven results.

The bottom line

NAD+ IV therapy is a premium-priced intervention whose marketing far outruns its evidence. The 2019 pilot measured the metabolome during a six-hour infusion ³; the 2026 retrospective pilot added short-term tolerability and exploratory biomarker data ¹². Neither establishes routine wellness efficacy. There are no randomized controlled trials showing IV NAD+ improves energy, focus, recovery, or aging. The (modest) human evidence that NAD+ can be raised at all comes from inexpensive oral precursors, and even those reliably raise the biomarker without reliably improving how people feel or function ⁸⁹¹⁰. Meanwhile a course of infusions can run into the low thousands of dollars.

If you're drawn to NAD+, the evidence-based move is to understand the whole picture first. Start with our NAD+ therapy evidence pillar, see how the precursors compare in NMN vs NR, and check how the products and providers stack up on our NAD+ rankings hub. One narrow place delivered NAD+ does have a real human signal is sudden hearing loss, where a small RCT used it as a supervised adjunct — we cover that honestly in NAD+ for hearing loss and tinnitus. Treat IV NAD+ as an expensive, unproven option — not the proven shortcut it's sold as.